NL0015000LC2 - Common Stock
MAINZ BIOMED NV
NASDAQ:MYNZ (7/1/2024, 7:00:02 PM)
After market: 0.345 0 (-0.06%)0.3452
-0.06 (-13.92%)
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The company is headquartered in Mainz, Hessen and currently employs 58 full-time employees. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
MAINZ BIOMED NV
Sirius Gutenberg Park, Robert-Koch-Strasse 50
MAINZ HESSEN
P: 4961315542860
Employees: 58
Website: https://www.mainzbiomed.com/
Which stocks are moving on Friday?
What's going on in today's session
Friday's session: top gainers and losers
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024...
Here you can normally see the latest stock twits on MYNZ, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: